In this episode of "The Top Line," we talk with Vimala Raghavendran, the vice president of informatics and product development at U.S. Pharmacopeia, about the factors causing the ongoing chemotherapy shortage. We also cover the Grail harassment lawsuits, CRISPR for Alzheimer's drug development, and the rest of the week's headlines. 

To learn more about the topics in this episode:
BridgeBio heart disease drug vindicated with phase 3 victory, plots FDA submission this year
The Future of Biotech
Grail sued by 3 women over alleged 'frat house' culture, harassment and retaliation
Scientists turn CRISPR scissors to genes involved in Alzheimer's
National cancer group reports widespread chemo shortages, calls on government and industry to help resolve them
FDA to allow temporary overseas production to shore up supplies of chemo drug
FDA can't solve drug shortages on its own, agency's oncology chief says

"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

In this episode of "The Top Line," we talk with Vimala Raghavendran, the vice president of informatics and product development at U.S. Pharmacopeia, about the factors causing the ongoing chemotherapy shortage. We also cover the Grail harassment lawsuits, CRISPR for Alzheimer's drug development, and the rest of the week's headlines. 
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/bridgebio-heart-disease-drug-vindicated-phase-3-victory-plots-fda-submission-23">BridgeBio heart disease drug vindicated with phase 3 victory, plots FDA submission this year</a></li>
<li><a href="https://www.fiercebiotechsummit.com/?utm_source=ppc&amp;utm_medium=google&amp;utm_campaign=fbs23&amp;gclid=CjwKCAjwwb6lBhBJEiwAbuVUSpPk1PPzUWIw-VBOgAvyXZSbJF2Qqryrb-VB45xiRroabTJFtHM9LhoCaWQQAvD_BwE" data-cke-saved-href="https://www.fiercebiotechsummit.com/?utm_source=ppc&amp;utm_medium=google&amp;utm_campaign=fbs23&amp;gclid=CjwKCAjwwb6lBhBJEiwAbuVUSpPk1PPzUWIw-VBOgAvyXZSbJF2Qqryrb-VB45xiRroabTJFtHM9LhoCaWQQAvD_BwE">The Future of Biotech</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/grail-sued-three-women-over-frat-house-culture-harassment-and-retaliation">Grail sued by 3 women over alleged 'frat house' culture, harassment and retaliation</a></li>
<li><a href="https://www.fiercebiotech.com/research/scientists-turn-crispr-scissors-genes-involved-alzheimers">Scientists turn CRISPR scissors to genes involved in Alzheimer's</a></li>
<li><a href="https://www.fiercepharma.com/pharma/national-cancer-center-network-reports-major-chemotherapy-shortages-calls-government">National cancer group reports widespread chemo shortages, calls on government and industry to help resolve them</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/fda-allow-temporary-overseas-production-shore-supplies-chemo-drug">FDA to allow temporary overseas production to shore up supplies of chemo drug</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/failure-market-results-persisting-shortages-fda-oncology-director-says-report">FDA can't solve drug shortages on its own, agency's oncology chief says</a></li>
</ul>
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement